World's Best Scientists 2026 revealed!
James J. Vredenburgh

James J. Vredenburgh

D-Index & Metrics

Medicine

D-Index
78
Citations
25397
World Ranking
17944
National Ranking
8951

James J. Vredenburgh publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James J. Vredenburgh sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 327 publications — 23rd percentile

23% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James J. Vredenburgh D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James J. Vredenburgh sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James J. Vredenburgh is affiliated with the Yale School of Medicine in the United States, focusing primarily on research within the field of Medicine. Their work spans several specialized subfields, including Pulmonary and Respiratory Medicine, Oncology, Genetics, Immunology, and Neurology.

The main research topics covered by James J. Vredenburgh include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Lung Cancer Treatments and Mutations
  • Lymphoma Diagnosis and Treatment
  • Immunotherapy and Immune Responses
  • Sarcoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments

Recent publications by Vredenburgh reflect a focus on oncology and cancer treatment, with significant contributions to research on glioblastoma, lung cancer, lymphoma, and immune biomarkers in myeloma. Selected papers include:

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma (2023, Journal of Clinical Oncology)
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial (2020, Clinical Cancer Research)
  • Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments (2022, Clinical Cancer Research)
  • Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma (2022, Cancer Cell)
  • Primary Bone Lymphoma: A Case Series and Review of Literature (2020, Case Reports in Hematology)

Frequent co-authors collaborating with Vredenburgh include:

  • Nerea Lopetegui-Lia
  • David A. Reardon
  • Henry S. Friedman
  • Annick Desjardins
  • John H. Sampson

The preferred publication venues for Vredenburgh's contributions are diverse but show repeated appearances in:

  • Cureus
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Cell
  • Case Reports in Hematology

Best Publications

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

    W P Peters;M Ross;J J Vredenburgh;B Meisenberg

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • Molecularly targeted therapy for malignant glioma

    Sith Sathornsumetee;David A. Reardon;Annick Desjardins;Jennifer A. Quinn

  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

    Paul G Richardson;Carol Murakami;Zhezhen Jin;Diane L Warren

  • Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.

    William P. Peters;Gary Rosner;Maureen Ross;James Vredenburgh

  • Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme

    David A. Reardon;Merrill J. Egorin;Jennifer A. Quinn;Jeremy N. Rich

  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

    John H. Sampson;Kenneth D. Aldape;Kenneth D. Aldape;Gary E. Archer;April Coan

  • Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population

    Paul G. Richardson;Anthony D. Elias;Amrita Krishnan;Catherine Wheeler

  • Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

    Sith Sathornsumetee;Yiting Cao;Jennifer E. Marcello;James E. Herndon

  • Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

    Jennifer A. Quinn;Sara Xiaoyin Jiang;David A. Reardon;Annick Desjardins

  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

    David A. Reardon;Annick Desjardins;James J. Vredenburgh;Sridharan Gururangan

  • Liver metastases from breast cancer: Long-term survival after curative resection

    Markus Selzner;Michael A. Morse;James J. Vredenburgh;William C. Meyers

  • Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

    Jennifer A. Quinn;Annick Desjardins;Jon David Weingart;Henry Brem

  • Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

    David A. Reardon;Gamal Akabani;R. Edward Coleman;Allan H. Friedman

  • Neurofibromatosis type 2

    S. Sathornsumetee;A. DesJardins;D. A. Reardon;J. N. Rich

Frequent Co-Authors

David A. Reardon
David A. Reardon Harvard University
Henry S. Friedman
Henry S. Friedman Duke University
James E. Herndon
James E. Herndon Duke University
John H. Sampson
John H. Sampson Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Roger E. McLendon
Roger E. McLendon Duke University
Darell D. Bigner
Darell D. Bigner Duke University
Nelson J. Chao
Nelson J. Chao Duke University
Patrick Y. Wen
Patrick Y. Wen Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While traditional medical school remains a common route, a growing number of healthcare professionals are choosing flexible online programs. If you’re considering advanced roles in medicine, nursing, or healthcare technology, online degrees open up a range of possibilities.

For those looking to become nurse practitioners or leaders in nursing, best online dnp programs can help you earn a Doctor of Nursing Practice with the flexibility of virtual study. Aspiring pharmacists can now explore pharm d online programs, allowing students to prepare for rewarding pharmacy careers without relocating.

Not every healthcare career requires patient care. If you are interested in data, technology, or organization, health information technology programs online provide a clear path into hospital administration, medical record management, and data security.

Additionally, there’s growing need for specialized roles like medical billers and coders. Many pursue certification through affordable online courses; you can learn more about medical coding certification cost to see if this career fits your goals.

Best Scientists Citing James J. Vredenburgh

Trending Scientists

Recently Published Articles